

Biocon Biologics Limited

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN**T** +91 080-6775 6775, **F** +91 080-6775 1030**E** contact@bioconbiologics.comwww.bioconbiologics.com

September 25, 2026

Singapore Exchange Securities Trading Limited

4 Shenton Way # 02-01

SGX Centre 2 Singapore 068807

Dear Sir/Madam,

Subject: Company Statement

Please find enclosed the company statement titled "*Biocon Malaysia Receives MHRA Approval for New Drug Product Fill Finish Unit for Insulins*".

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

Akhilesh Nand

Company Secretary

Membership No. ACS 13669

Encl: as above



NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

**Biocon Malaysia Receives MHRA Approval for New Drug
Product Fill Finish Unit for Insulins**

Bengaluru, Karnataka, India, September 25, 2026

Biocon Limited (BSE code: 532523, NSE: BIOCON) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA), UK for its new drug product fill finish unit for Semglee® (insulin glargine) at its insulin manufacturing facility in Malaysia.

In July, Biocon had secured [regulatory approval from the European Medicines Agency \(EMA\)](#) for this new drug product fill-finish line.